As part of the Surgical Grand Round lecture series, hosted by the Nuffield Department of Surgical Sciences, Dr Simon Buczacki (Academic Consultant Colorectal Surgeon at Addenbrooke’s Hospital in Cambridge) will be discussing ‘Small intestinal neuro-endocrine tumours – surgery and science in Cambridge’.

As part of the NIHR Oxford Biomedical Research Centre’s Open Day, a panel of experts will discuss how artificial intelligence can be used to benefit patients and the challenges that it presents. The discussion will be chaired by Professor Lionel Tarassenko, world-leading expert in the application of signal processing to medical systems.

As part of the NIHR Oxford Biomedical Research Centre’s Open Day, Professor Ian Pavord will discuss emerging treatments for asthma, a condition that affects 5.4 million people in the UK. Professor Pavord is an internationally renowned researcher with a particular interest in asthma, chronic pulmonary disease and chronic cough.

As part of the NIHR Oxford Biomedical Research Centre’s Open Day, Dr David Eyre, an infectious diseases researcher and clinician, and Dr Katie Jeffery, Consultant in Microbiology at Oxford University Hospitals NHS Foundation Trust, will discuss how they used infection prevention and control best practice, whole genome sequencing and electronic patient data to halt an outbreak of a potentially deadly fungal pathogen at the John Radcliffe Hospital between 2015 and 2017.

The 5th Annual Oxford Business and Poverty Conference will feature a diverse range of speakers addressing the Paradoxes of Prosperity. Sign up here: https://www.eventbrite.com/e/5th-annual-oxford-business-poverty-conference-tickets-57733957822
Hosted at the Sheldonian Theatre, the conference will feature keynotes by:
Lant Pritchett: RISE Research Director at the Blavatnik School of Government, former Senior Fellow at the Center for Global Development
Efosa Ojomo: Global Prosperity Lead and Senior Researcher at the Clayton Christensen Institute
John Hoffmire: Director of Center on Business and Poverty and Research Associate at Kellogg Colleges at Center For Mutual and Employee-owned Business at Oxford University
Ananth Pai: Executive Director, Bharath Beedi Works Pvt. Ltd. and Director, Bharath Auto Cars Pvt
Laurel Stanfield: Assistant Professor of Marketing at Bentley College in Massachusetts
Grace Cheng: Greater China’s Country Manager for Russell Reynolds Associates
Madhusudan Jagadish: 2016 Graduate MBA, Said Business School, University of Oxford
Tentative Schedule:
2:15-2:20 Welcome
2:20-2:50 Efosa Ojomo, co-author of The Prosperity Paradox, sets the stage for the need for innovation in development
2:50-3:20 John Hoffmire, Ananth Pai and Mudhusudan Jagadish explain how the Prosperity Paradox can be used in India as a model to create good jobs for poor women
3:20-3:40 Break
3:40-4:10 Laurel Steinfeld speaks to issues of gender, development and business – addressing paradoxes related to prosperity
4:10-4:40 Grace Cheng, speaks about the history of China’s use of disruptive innovations to develop its economy
4:40-5:15 Break
5:15-6 Lant Pritchett talks on Pushing Past Poverty: Paths to Prosperity
6:30-8 Dinner at the Rhodes House – Purchase tickets after signing up for the conference
Sponsors include: Russell Reynolds, Employee Ownership Foundation, Ananth Pai Foundation and others

As part of the Surgical Grand Round lecture series, hosted by the Nuffield Department of Surgical Sciences:

Dr Anita Makins will present ‘FGM: a global perspective’

Dr Katy Newell-Jones will present ‘Medicalisation of female genital cutting: decision making dilemmas and competing priorities’

Professor Chris Lavy will present ‘Building kids’ hospitals in Africa: the need, the realities and the rewards’

As part of the Surgical Grand Rounds lecture series, hosted by the Nuffield Department of Surgical Sciences, Professor Richard van Hillegersberg from University Medical Center Utrecht in The Netherlands will discuss ‘Robotic minimally invasive oesophagectomy’.

In this lecture, lawyer Mary Bartkus shares her firsthand experience of the international litigation of multibillion dollar claims against Big Pharma when a medication taken by millions of users worldwide is withdrawn.

She will address the impact of the withdrawal and United States litigation on regulators, legislators, and on cross-border litigation in common law and civil law jurisdictions across six continents.

When Merck & Co., Inc. withdrew the innovative painkiller Vioxx (Rofecoxib) from more than eighty countries following evidence that high-dosage use could cause an increased risk of heart attack and stroke, thousands of US citizens brought personal injury claims.

A Texas jury awarded more than $250 million to one individual claimant. Although that verdict was reduced and later overturned on appeal, and most US juries found for the company, with more than 26,000 US court claims yet to be tried and another 14,100 waiting to be filed, the company agreed to resolve the US personal injury claims for $4.85 billion, a deal said to be “favourable” to the company and “clearly at the low end of general expectations”.

Internationally, claims were brought in waves following developments in the US. These international cases would be heard and decided in jurisdictions with different traditions and conditions for litigants.

In Australia, a justice of the Federal Court dismissed all claims against Merck & Co., Inc. in class litigation, finding “Merck had done everything that might reasonably be expected of it in the discharge of its duty of care”. The Full Court overturned an award of damages to the individual representative claimant for failure to establish causation, and awarded full costs to the company; the High Court denied claimants leave to appeal. Claims of remaining group members then were resolved.

In England, claimants abandoned multi-party actions filed in the High Court. In Scotland, the parties litigated and resolved individual actions. In Canada, the parties litigated and resolved overlapping class and individual actions in ten provinces. Courts regularly dismissed cases in civil law jurisdictions.

The lecture considers this landmark international litigation alongside the challenges companies face when investing billions of dollars to develop innovative medications, and asks: Who won and who lost?

Mary E. Bartkus is Special Counsel at Hughes Hubbard & Reed LLP, a member of the Bars of New York and New Jersey; previously Executive Director & Senior Counsel, Merck & Co., Inc.

Under the leadership of the new Climax Chair of Clinical Therapeutics, Professor Duncan Richards, St Hilda’s College is establishing an innovative research centre aimed at addressing some of the key questions facing Clinical Therapeutics today.

We are launching this initiative on 11th June 2019, when Sir Michael Rawlins GBE, MD, FRCP, FMedSci , Chair of the UK Medicines and Healthcare products Regulatory Agency, will deliver the centre’s inaugural lecture: ‘Novel approaches to assessing the safety and efficacy of new medicines’.

As part of the Surgical Grand Rounds lecture series, hosted by the Nuffield Department of Surgical Sciences:

Mr Ravish Jootun will present “Towards 0% 90-day Colorectal mortality: Accepting a low floor in the anastomotic leak rate plus safe rescue using an early warning integrated model”

Mr Will Perry will present “University of Auckland’s Global Surgery Group: the Republic of Vanuatu – a growing collaboration”

Interested in medical device regulation? Get together with experts within the University and other researchers to discuss aspects of Medical Device Regulation relevant to your innovation. You can join us online at the comfort of your own desk!

Topic: Software classification

Who should attend? People interested in bringing a medical device to the market or interested in the medical device regulation.

Joining instructions: Further instructions on how to join the Zoom webinar will be made available to you after registration of the event

Professor Carl Heneghan will talk about his involvement in Tamiflu research that led to the discovery of 170,000 pages of clinical study reports, the subsequent development of Alltrials he was involved in and the current epidemic of publication and reporting bias that plagues much of the current research evidence.

Carl Heneghan, Professor of Evidence-Based Medicine, employs evidence-based methods to research diagnostic reasoning, test accuracy and communicating diagnostic results to a wider audience.

This talk is being held as part of the Practice of Evidence-Based Health Care module which is part of the MSc in Evidence-Based Health Care and the MSc in EBHC Systematic Reviews. Members of the public are welcome to attend.

As part of the Surgical Grand Rounds lecture series, hosted by the Nuffield Department of Surgical Sciences, Professor Michael Griffin OBE will present ‘Talking to cancer patients – do not promise what you cannot deliver’.

Professor Michael Griffin OBE became President of the Royal College of Surgeons of Edinburgh in 2018, when he was a Consultant Oesophagogastric surgeon at the Royal Victoria Infirmary. He developed the Northern Oesophagogastric Cancer Unit which is now the largest in Europe and North America. A Council member since 2009, he is Chair of the Joint Committee for Intercollegiate Examinations (JCIE) and Professor of Gastrointestinal Surgery at the University of Newcastle upon Tyne. His clinical and research interests have been focused on early diagnosis and radical treatment of oesophagogastric cancers. He was awarded an OBE for services to cancer health care in 2013.

Breakthroughs using gene therapy and gene editing are regularly in the news, but how close in reality are we to them to be used to treat actual patients? Professor of Molecular Therapy and Co-Director of the Gene Medicine Research Group, Steve Hyde sorts the fact from the fiction as he discusses how viruses are being re-purposed to treat rare diseases such as leukaemia, blindness and haemophilia.

As part of the Surgical Grand Round lecture series, hosted by the Nuffield Department of Surgical Sciences, Mr Vincent Gnanapragasam from the University of Cambridge will discuss ‘Using research to change paradigms in diagnosing and managing early prostate cancer’.

As part of the Surgical Grand Round lecture series, hosted by the Nuffield Department of Surgical Sciences, Professor Chris Lavy from the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences will present ‘Public-private partnerships in elective surgery’.

The logic and principles behind the drive for evidence-based health care are so compelling that often the limitations of evidence go unacknowledged. Despite a strong evidence base demonstrating the health risks associated with higher body weights, and health professionals routinely instructing patients to lose weight to improve their health, the incidence of obesity is predicted to continue to rise. Calling on his research into the relationships between obesity, inequality and health, Oli Williams – a fellow of The Healthcare Improvement Studies Institute – will argue that when it comes to reducing the burden on, and improving, health care a more critical approach to the way we generate, select, apply and communicate evidence is needed.

Oli Williams completed his PhD in the Department of Sociology at the University of Leicester. He was subsequently awarded the NIHR CLAHRC West Dan Hill Fellowship in Health Equity which he held at the University of Bath. He later re-joined the University of Leicester in the Department of Health Sciences working in the SAPPHIRE Group and is now based at King’s College London after being awarded a THIS Institute Postdoctoral Fellowship. His research focuses on health inequalities, the promotion of healthy lifestyles, obesity, weight stigma, equitable intervention and co-production. He co-founded the art collective Act With Love (AWL) to promote social change. The Weight of Expectation comic is one example of their work, view others at: www.actwithlove.co.uk In recognition of his work on weight stigma the British Science Association invited Oli to deliver the Margaret Mead Award Lecture for Social Sciences at the British Science Festival 2018.

This talk is being held as part of the Qualitative Research Methods course which is part of the Evidence-Based Health Care Programme. This is a free event and members of the public are welcome to attend.

Join us to learn about the progress being made in biomaterials, the next generation of innovative solutions that aim to tackle current health challenges, and what it takes to start your own venture. The event will feature talks from two prominent individuals, Dr Nick Skaer (CEO of Orthox) and Dr Nick Edwards (Co-Founder of MedInnovate and Chairman of Satie8). Dr Skaer has over 25 years’ experience in life science and materials research, and 14 years as a medtech CEO, raising over £18m. Dr Edwards has over 30 years’ experience in supporting pharmaceutical companies as ex- Global Lead of Accenture’s Pharmaceutical R&D business and current Chairman of Prescient Healthcare Group. He is a Founder of MedInnovate and an investor and supporter of life-science start-ups as well as current Chairman of Satie8.

There will be a networking & drinks reception after the event.

The event is free as always. Spots are limited, so get registered today on:

https://www.eventbrite.co.uk/e/the-next-generation-of-medical-devices-tickets-76955848013

This is an exclusive event brought to you by the SIU in partnership with the Oxford Pharmacology Society. The application of big data and genomics in healthcare is vast, with tremendous opportunities to revolutionise current methods of diagnosing and treating diseases. Although, patient specific data is a powerful tool that can accelerate the development and translation of novel drugs and therapeutics, there are limitations to overcome. This event will take a closer look at the role of industries, academics, clinicians and healthcare policy makers in encouraging the translation of ideas into real-world solutions and the challenges within each sector. To discuss this, we will be hosting Dr Jeffrey Barrett (CSO and Director of Genomics Plc), Dr Michelle van Velthoven (Sir David Cooksey Fellow in Healthcare Translation at the University of Oxford) and Dr Amitava Banerjee (Associate Professor in Clinical Data Science at University College London).
The event will be on the 20th November at 17h30pm – 19h00, in the Department of Pharmacology. There will be a free networking & drinks reception after the event.
The event is free as always. Spots are limited, so get registered today on https://www.eventbrite.co.uk/e/pharma-and-big-data-the-healthcare-revolution-tickets-80628276345

Should doctors with commercial interests lead research on their products? Should we forget ‘conflicts’ and discuss ‘declarations of interest’ instead? Who should hold and maintain conflicts of interest registers for doctors? Should practicing doctors work with the pharma industry as well as serve on guideline committees? Should researchers with extensive financial interests be disqualified from studies of their own products?

The Physician Payments Sunshine Act requires US manufacturers to collect, track and report all financial relationships with clinicians and teaching hospitals. Professor Heneghan will discuss the failings with the current system of reporting of conflicts in medicine, what’s been tried so far, and why it is time for a UK Sunshine Act.

Carl Heneghan, Professor of Evidence-Based Medicine, employs evidence-based methods to research diagnostic reasoning, test accuracy and communicating diagnostic results to a wider audience.

This talk is being held as part of the Practice of Evidence-Based Health Care module which is part of the MSc in Evidence-Based Health Care and the MSc in EBHC Systematic Reviews. Members of the public are welcome to attend.

Overdiagnosis is the diagnosis of “disease” that will never cause symptoms or death during a patient’s lifetime.

Recent results of the NELSON Lung Cancer Screening Trial reports reductions in lung-cancer survival but not overall survival – The desire to detect disease even earlier means Overdiagnosis is on the rise, however, the interpretation of screening trial results is problematic and often gives rise to significant uncertainties that go unanswered.

Carl Heneghan, Professor of Evidence-Based Medicine, employs evidence-based methods to research diagnostic reasoning, test accuracy and communicating diagnostic results to a wider audience.

This talk is being held as part of the Evidence-Based Diagnosis & Screening module which is part of the MSc in Evidence-Based Health Care and the MSc in EBHC Medical Statistics. Members of the public are welcome to attend.

In this book talk, Claas will review central findings of his research on the past 80 years of antibiotic use, resistance, and regulation in food production with introduction by Prof Mark Harrison, Director of Wellcome Centre for Ethics and Humanities.

Mass-introduced after 1945, antibiotics helped revolutionise food production. Farmers and veterinarians used antibiotics to prevent and treat disease, protect plants, preserve food, and promote animals’ growth. Many soon became dependent on routine antibiotic use to sustain and increase production. The resulting growth of antibiotic infrastructures came at a price. Critics blamed antibiotics for leaving dangerous residues in food, enabling bad animal welfare, and selecting for antimicrobial resistance (AMR) in bacteria, which could no longer be treated with antibiotics.

Pyrrhic Progress analyses over 80 years of evolving non-human antibiotic use on both sides of the Atlantic and introduces readers to the historical and current complexities of antibiotic stewardship in a time of rising AMR.

This talk includes a drinks reception and nibbles, all welcome

In modern high-tech health care, patients appear to be the stumbling block.

Uninformed, anxious, noncompliant individuals with unhealthy lifestyles who demand treatments advertised by celebrities and insist on unnecessary but expensive diagnostics may eventually turn into plaintiffs. But what about their physicians? About ten years ago, Muir Gray and Gerd Gigerenzer published a book with the subtitle “Envisioning health care 2020”. They listed “seven sins” of health care systems then, one of which was health professionals’ stunning lack of risk literacy. Many were not exactly sure what a false-positive rate was, or what overdiagnosis and survival rates mean, and they were unable to evaluate articles in their own field. As a consequence, the ideals of informed consent and shared decision-making remain a pipedream – both doctors and patients are habitually misled by biased information in health brochures and advertisements. At the same time, the risk literacy problem is one of the few in health care that actually have a known solution. A quick cure is to teach efficient risk communication that fosters transparency as opposed to confusion, both in medical school and in CME. It can be done with 4th graders, so it should work with doctors, too.

Now, in 2020, can every doctor understand health statistics? In this talk, Gerd Gigerenzer will describe the efforts towards this goal, a few successes, but also the steadfast forces that undermine doctors’ ability to understand and act on evidence. Moreover, the last decade has seen two new forces that distract from solving the problem. The first is the promise of digital technology, from diagnostic AI systems to big data analytics, which consumes much of the attention. Digital technology is of little help if doctors do not understand it. Second, our efforts to make patients competent and to encourage them to articulate their values are now in conflict with the new paternalistic view that patients just need to be nudged into better behaviour.

This talk will be followed by a drinks reception, all welcome

Joint event with: The Oxford–Berlin Research Partnership

With the UK population predicted to grow nearly 20% by 2050 (circa 77 million people), over 65s making up around 25% of the population and more and more demands being put on the healthcare system what does the future hold?

Professor Chris Whitty, England’s Chief Medical Officer, will discuss predictions for the future advancement of healthcare in the UK and how these advancements will monitor, diagnose and treat us and how this will change our healthcare system.

Part of the Oxford Martin School Lecture Series: ‘Shaping the future’

Snakebite is arguably the world’s biggest hidden health crisis. It kills some 120,000 people every year, mostly from the world’s poorest communities in rural Africa, Asia and South America. The burden of death and disability is equivalent to that of prostate cancer or cervical cancer and greater than that of any other neglected tropical disease. Yet the problem is solvable – we need to bring snakebite treatment into the 21st century; we need innovative approaches to discovering and developing next generation snakebite treatments; and we need to build and importantly, sustain snakebite as a global health priority.

Dr Nick Cammack was appointed to the Wellcome Trust in September 2019 to lead an ambitious new £80 million programme aimed at driving a step-change in snakebite treatment around the world. The goal is to achieve a 50% reduction in mortality by 2030. In addition there is a pressing need to modernise the production of anti-venoms and improve their means of delivery.

Adults make choices regarding the technology they use to self-manage their health and wellbeing, and these technologies are often adopted, used and abused in ways that researchers, manufacturers, and clinicians have not accounted for. This talk will give an overview of human-computer interaction qualitative research on the real world use of mobile technologies in people’s everyday lives. Accounting for individual health and wellbeing choices adults make with technology, supporting choices through end user customisation, and the emerging trend towards Do-It-Yourself open-source health and wellbeing technology will be discussed. Examples of pragmatic qualitative studies will be given from research on wearables, apps, and standalone devices used for Type 1 diabetes, hearing loss, baby monitoring, and physical fitness.

Dr Aisling O’Kane is a Senior Lecturer in Human-Computer Interaction for Health and Deputy Director of the EPSRC CDT in Digital Health and Care at the University of Bristol. As a member of the Bristol Interaction Group and the Digital Health Engineering Group, she uses a pragmatic approach to qualitative research of health, wellbeing and care technologies. Dr O’Kane is currently PI of Innovate UK Machine Learning for Diabetes, co-designing AI to support diabetes self-management and Co-I of EPSRC SPHERE Next Steps, co-designing smart home technology to support health at home.

This talk is being held as part of the Advanced Qualitative Research Methods course which is part of the Evidence-Based Health Care Programme. This is a free event and members of the public are welcome to attend.

Join Professor Chas Bountra, Professor of Translational Medicine and Professor Sir Charles Godfray as they discuss how the healthcare system has had to adapt due to the Covid-19 pandemic and what this means in the future.

With COVID-19 vaccines on the horizon, attention again returns to the contentious topic of whether vaccination should be made mandatory.

Recent polling has resulted in worrying headlines about a lack of willingness to have a COVID-19 vaccine if it were available.

Are mandates the answer to ensure vaccine high uptake to end the pandemic? While still a hypothetical scenario, without yet having a safe and effective vaccine approved for use, this could change in the coming months. The question of introducing mandatory vaccination spans considerations of personal liberty, health decision-making, public health and policy, as well as the relationship between the state and its citizens. Join Professor Julian Savulescu and Dr Samantha Vanderslott to debate the ethical and public policy arguments for and against mandatory COVID-19 vaccination.

On the 30th November it was announced that the Artificial Intelligence computer programme AlphaFold had made a decisive breakthrough in the determination of the 3-D structures of proteins.

The announcement was immediately hailed as one of the major scientific advances of the decade.

Why is it important to understand the 3-D structures of protein, why are they difficult to construct, and what is the nature of AlphaFold’s advance? Why is this so exciting and what further advances in medicine and the other biosciences may result? To find out, join a conversation between Yvonne Jones, Director, Cancer Research UK Receptor Structure Research Group and Charles Godfray, Director, Oxford Martin School, who will explore these fascinating issues.